trending Market Intelligence /marketintelligence/en/news-insights/trending/ox5uopk2nu0a2slbfueika2 content esgSubNav
In This List

Acorda Therapeutics chief technology officer to resign

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes

Blog

Investment Banking Essentials Newsletter April Edition - 2022


Acorda Therapeutics chief technology officer to resign

Acorda Therapeutics Inc. said Rick Batycky is leaving as the company's chief technology officer, effective Aug. 20, to be the CEO of a privately held, venture-backed biotechnology company.

David Lawrence, chief of business operations, will take over the position for Acorda's Chelsea, Mass.-based manufacturing facility, which produces Inbrija, a drug indicated to treat symptoms of so-called off periods — times when the effects of a medication wears off — in Parkinson's disease. He will also handle the external manufacturing of Ampyra, a medication to help improve walking in adults with multiple sclerosis.

In addition, Chief Medical Officer Burkhard Blank will lead the company's pharmaceutical development and technical operations team.

Ardsley, N.Y.-based Acorda Therapeutics is a biopharmaceutical company that develops therapies to restore function and improve the lives of people with neurological disorders.